Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Orally bioavailable thrombin inhibitors designed at Pfizer

June 1, 2000

Antiplatelet effects reported for new cell adhesion inhibitors from Takeda

June 1, 2000

Angiomax approvable for use as anticoagulant

May 26, 2000

Lilly prepares potent and orally active thrombin inhibitors

May 25, 2000

Neutralase studied in percutaneous coronary intervention trial

May 23, 2000

FDA denies approval for Refludan in acute coronary syndrome

May 19, 2000

Genzyme Transgenics and Genzyme General receive orphan drug designation

May 18, 2000

Eryloside F: a new thrombin receptor antagonist produced by a marine sponge

May 17, 2000

Glaxo Wellcome reveals recent findings in its thrombin inhibitor program

May 17, 2000

Pharmacological profile of SL-650472, a novel antiplatelet, antithrombotic agent

May 15, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...